Cancer Prevention II

ISBN 10: 3540692967 / ISBN 13: 9783540692966

Published by Springer, 2009

About this Item

Zustandsbeschreibung: Einband leicht bestoßen. Edited by Hans-Jörg Senn, Ursula Kapp and Florian Otto. 251 Seiten, gebunden (Recent Results iin Cancer Research; Band 181/Springer-Verlag 2009). Statt EUR 123,00. Gewicht: 578 g - Gebunden/Gebundene Ausgabe.

Seller Inventory # 934045

Bibliographic Details

• Title: Cancer Prevention II
• Publisher: Springer
• Publication Date: 2009
• Language: English
• ISBN 10: 3540692967
• ISBN 13: 9783540692966
• Binding: Hardcover
• Condition: Wie Neu
• Weight: 578 grams
• Seller catalogs:
  • Medizinische Fachliteratur

About this title

Synopsis

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland―and we fear in many other parts of the globe―some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.